Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1186/s40510-024-00552-0 | DOI Listing |
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699026 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Correction to: Effect of anti-sclerostin antibody on orthodontic tooth movement in ovariectomized rats.
Prog Orthod
January 2025
Institute for Innovation in Digital Healthcare (IIDH), Yonsei University Health System, Seoul, Korea.
Reversal of the diabetic bone signature with anabolic therapies in mice.
Bone Res
April 2023
Department of Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
The mechanisms underlying the bone disease induced by diabetes are complex and not fully understood; and antiresorptive agents, the current standard of care, do not restore the weakened bone architecture. Herein, we reveal the diabetic bone signature in mice at the tissue, cell, and transcriptome levels and demonstrate that three FDA-approved bone-anabolic agents correct it. Diabetes decreased bone mineral density (BMD) and bone formation, damaged microarchitecture, increased porosity of cortical bone, and compromised bone strength.
View Article and Find Full Text PDFDevelopment of selective bispecific Wnt mimetics for bone loss and repair.
Nat Commun
May 2021
Surrozen, Inc., South San Francisco, CA, USA.
Article Synopsis
- The Wnt signaling pathway plays a critical role in regulating bone mass in both humans and rodent models, and researchers have developed a new antibody-based platform to create effective Wnt mimetics.
- These engineered bi-specific Wnt mimetics target specific proteins to enhance bone growth in mice, demonstrating significant improvements in various bone-related conditions like osteoporosis and fractures.
- Combining these Wnt mimetics with existing treatments like bisphosphonates enhances bone accrual, suggesting their potential for treating conditions related to low bone mineral density.
Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study.
Bone Rep
June 2021
Department of Orthopaedic Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan.
Real-world data on the new anti-sclerostin antibody drug, romosozumab, remain scarce. There is a strong need to accumulate and analyze data on romosozumab treatment for such conditions as osteoporosis. The purpose of this study was to investigate the therapeutic and adverse effects of romosozumab for osteoporosis treatment in clinical practice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!